Aspirin inhibits NF-kappaB and protects from angiotensin II-induced organ damage.
Muller
D N
DN
Franz Volhard Clinic, Medical Faculty of the Charité, Humboldt University of Berlin, Berlin, Germany.
Heissmeyer
V
V
Dechend
R
R
Hampich
F
F
Park
J K
JK
Fiebeler
A
A
Shagdarsuren
E
E
Theuer
J
J
Elger
M
M
Pilz
B
B
Breu
V
V
Schroer
K
K
Ganten
D
D
Dietz
R
R
Haller
H
H
Scheidereit
C
C
Luft
F C
FC
D000804:Angiotensin II; D000808:Angiotensinogen / Q000235:genetics; D000818:Animals; D030801:Animals, Genetically Modified; D001241:Aspirin / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D015496:CD4-Positive T-Lymphocytes / Q000473:pathology; D018414:CD8-Positive T-Lymphocytes / Q000473:pathology; D015870:Gene Expression; D006331:Heart Diseases / Q000139:chemically induced / Q000517:prevention & control*; D006801:Humans; D051550:I-kappa B Kinase; D007668:Kidney / Q000098:blood supply / Q000737:chemistry; D007674:Kidney Diseases / Q000139:chemically induced / Q000517:prevention & control*; D008264:Macrophages / Q000473:pathology; D009000:Monocytes / Q000473:pathology; D009205:Myocarditis / Q000473:pathology / Q000517:prevention & control; D009206:Myocardium / Q000737:chemistry; D016328:NF-kappa B / Q000037:antagonists & inhibitors*; D009393:Nephritis / Q000473:pathology / Q000517:prevention & control; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors; D051381:Rats; D012083:Renin / Q000235:genetics; D018808:Transcription Factor AP-1 / Q000037:antagonists & inhibitors; D019010:Vascular Cell Adhesion Molecule-1 / Q000032:analysis
D016328:NF-kappa B; D018808:Transcription Factor AP-1; D019010:Vascular Cell Adhesion Molecule-1; D000808:Angiotensinogen; D000804:Angiotensin II; D017346:Protein Serine-Threonine Kinases; C496559:CHUK protein, human; D051550:I-kappa B Kinase; C496560:IKBKB protein, human; C496565:IKBKE protein, human; D012083:Renin; D001241:Aspirin